Published in final edited form as:

Chem Commun (Camb). 2015 January 31; 51(9): 1662–1665. doi:10.1039/c4cc08809c.

Cellular activity of siRNA oligonucleotides containing synthetic isomorphous nucleoside surrogates

Dongwon Shin^a, Peter Lönn^b, Steven F. Dowdy^b, and Yitzhak Tor^{a,*}

^aDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093-0358, USA

^bCellular & Molecular Medicine, University of California, San Diego, La Jolla, CA 92093-0686, USA

Abstract

Singly and multiply modified synthetic siRNA oligonucleotides, containing isomorphous surrogate nucleobases, show high interference potency in cell culture, suggesting the highly isomorphous RNA alphabet, based on a thieno[3,4-*d*]-pyrimidine core, is tolerated well by the cellular silencing machinery.

RNA interference (RNAi), a regulatory process induced by short interfering RNA (siRNA), is a powerful process capable of altering cellular phenotypes,^{1–6} deciphering genetic pathways^{7–8} and identifying new therapeutic targets.^{9–10,11} Short double stranded RNA oligonucleotides are either generated endogenously by Dicer from longer precursors, or delivered exogenously. The passenger strand gets degraded, while the guide strand, loaded onto the RNA-induced silencing complex (RISC), guides the degradation of matched homologous mRNA sequences at a specific site (Figure 1). Related pathways mediated by micro- (miRNAs) or dicer-independent RNAs (piRNAs) have also been described.¹² The exquisite selectivity for all human mRNA targets has made RNAi the focus of intense research. Its promise to facilitate personalized medicine and to keep pace with evolving pandemics has made this technology vital for future therapeutic development. This potential has prompted the exploration of diverse chemical modifications with the hope of altering the activity, selectivity, stability and potency of therapeutically-relevant siRNAs. Numerous backbone and ribose modifications have been examined in siRNA.^{13–17} Much less has been done, however, with nucleobase surrogates capable of closely mimicking the native heterocycles.^{18–20} Such modified isomorphous nucleosides have the potential to impact the cellular interference activity and to serve as built-in probes, potentially assisting in correlating biophysical properties with biological activity. Here we systematically explore the cellular silencing activity and biophysical properties of eighteen siRNA oligonucleotides, modified with a recently introduced isomorphous RNA alphabet (Figure 2).²¹ We modify the guide strand at 13 out of the 21 possible nucleotide positions, including the seed region, investigating the effect of individual as well as multiple modifications on the stability of the guide/passenger duplex and on the *in vitro* interference potency. Our

*Correspondence to: ytor@ucsd.edu.

results illustrate that this alternative alphabet is well tolerated biophysically and cellularly, with oligonucleotides containing single substitutions displaying the same (or enhanced) activity compared to the native unmodified siRNAs. Multiple modifications were also well-accommodated, even with multiple base substitutions within the critical seed region. Importantly, a qualitative correlation is seen between the thermodynamic stability of the guide/passenger duplex and cellular interference activity.

We have recently reported the preparation of an alternative RNA alphabet, where all nucleosides were derived from thieno[3,4-*d*]pyrimidine as the common heterocyclic nucleus (Figure 2).²¹ Structural analysis of their crystal structures suggested high level of “isomophicity”. While some perturbations to the D-ribose pucker were seen, all modified ribonucleosides displayed an *anti* orientation at their glycosidic linkage, similar to the preference seen with the native nucleosides.²² A more critical test, assessing the potential utility of this alternative RNA alphabet, would be to evaluate their impact on the biophysical features and function of biologically relevant oligonucleotides. Although likely to be context, system and sequence dependent, we felt rigorously evaluating their *in vitro* RNA interference activity in cell culture would provide useful insight into their ability to properly replace the native nucleobases in a functionally-demanding context and perhaps inspire future utilizations.

To explore the compatibility of the isosteric RNA alphabet shown in Figure 2 with the cellular interference machinery, an established siRNA sequence, known to target a destabilized green fluorescent protein (dGFP) in human H1299 lung adenocarcinoma reporter cell line,²³ was selected. This assay has proven to be a sensitive and robust platform for evaluating cellular siRNA activity.^{7–8} Following the selection of a reporter assay, which identifies a specific siRNA sequence, specific modification positions needed to be selected. Although all positions can, in principle, be modified, we have identified selected positions to challenge the alternative alphabet. Specifically, modifications have been introduced into the seed region as well as opposite the cleavage site.

Eighteen single stranded oligonucleotides, **5–22**, containing thieno[3,4-*d*]pyrimidine-based nucleosides replacing their natural counterparts at a single or multiple substitutions in the guide strand, were prepared (Table 1). The new nucleobases were strategically placed to explore the impact of the surrogate nucleobases on positions naturally occupied by both pyrimidines and purines. Additionally, substitutions were made to explore their impact in distinct domains within the 21-mer siRNA guide strand, including residues 2–8 at the 5'-end, known as the seed region, and substitutions neighboring or opposite the RISC induced cleavage site.

The modified 21-mer RNA oligonucleotides were all prepared using solid-phase synthesis (Table 1). The required protected phosphoramidites of **thG**, **thA**, **thU** and **thC** have been synthesized as shown in Scheme 1 relying, in the case of the purine analogs **thG** and **thA** (whose synthesis is more demanding), on the simultaneous protection of the 3' and 5' hydroxyls using di-*tert*-butylsiloxane to facilitate selective TBDMS protection of the 2'-hydroxyl.²⁴ Following completion of the solid phase synthesis, the oligonucleotides were

deprotected and purified by PAGE. They were further characterized by MALDI-TOF mass spectrometry (Table S1).

Prior to evaluating the cellular activity of the modified siRNAs, their duplex stability was assessed. The effect of base substitutions on the thermal stability of the resulting siRNA duplexes formed upon hybridization to the corresponding passenger strand was first examined and compared to the unmodified siRNA duplex **1•2** (Table 1). Singly modified siRNAs, incorporating the purine mimics thA and thG, appear to be more stable than their unmodified natural counterpart, where duplex stabilization of about + 0.5 °C per modification is observed at pH 7.0 (20 mM sodium cacodylate, 20 mM NaCl). The single exception was the modification in position G4, which was slightly destabilizing by –0.5 °C. Duplex siRNA oligonucleotides, containing the pyrimidine mimics thU and thC, were destabilized by –0.4 to –2.9 °C per base modification, when compared to the native duplex. Multiple incorporation of pyrimidine mimics yielded siRNA oligonucleotides, which were destabilized by –1.5 °C and –1.0 °C per modification for U2•6 (**1•16**) and C8•10 (**1•19**), respectively. In contrast, a duplex incorporating two thA at positions A11 and A15 (**1•22**) was found to be stabilized by +1.6 °C per modification, yielding a double stranded construct which appears more stable than the corresponding singly modified duplexes with thA at positions A11 or A15 (**1•20** and **1•21**, respectively).

siRNA-mediated interference studies were conducted in H1299 cells with a dGFP reporter gene as described.²³ All modified siRNA duplexes containing thA, thC, thG and thU substitutions were examined and compared to the activity displayed by the unmodified RNA (WT) and a Luciferase2-specific siRNA (as a negative control).²³

Although the deviation in thermal stability of all modified siRNAs appears to be relatively subtle when compared to the unmodified siRNA duplex, native polyacrylamide gels were run before all transfection experiments (see Figure S1). The cells were transfected using lipofectamine with 1–50 nM of dsRNA in the cell media. Interference was evaluated by measuring the level of GFP expression at 24, 48 and 72 hr using flow cytometry. Figure 3 shows the data corresponding to 48 hr and additional time points (for 24 and 72 hours) are provided in the Supplementary Information (see Figure S2). Figure 4 depicts the normalized interference activity with respect to the native siRNA shown along the thermal stability of each duplex. The following sections summarize the interference observed per modification.

Interference results for siRNA duplexes containing guide strand modifications with thG replacing the native G in positions 4, 7, 13, 16 and 19 are shown in Figure 3. These modified duplexes were nearly as effective as the WT sequence in all concentrations, with the exception of the G4 substitution (**1•5**), which showed slightly attenuated activity and G13 (**1•7**), which consistently showed enhanced activity when compared to the positive control (Figure 4).

This particular siRNA contains only two A residues at positions 11 and 15 in the guide strand. Their substitution for thA yielded little effect on cellular mRNA degradation compared to the unmodified WT for both singly and doubly modified siRNAs (Figure 3).

This is of significance, since A11 is near the cleavage site of the target mRNA, demonstrating unperturbed function by a strategically modified siRNA.

Substituting U for thU at positions 2, 6, 9 and 14 in the guide strands **12–15**, respectively, was somewhat disruptive for RNAi activity (Figure 3). In particular, incorporating thU at positions 2 and 9 (**1•12** and **1•14**, respectively), flanking the seed region, were most detrimental (Figure 4) with up to 25% attenuation in interference activity with 5 nM duplex concentration at 48 hours. Interestingly, and in stark contrast to the behavior seen with residues 2 and 9, substituting U6 within the seed region with thU (**1•13**) retained gene silencing activity at levels close to the RNAi activity displayed by the WT oligonucleotide. Incorporating thU at position 14, toward the 3'-end of the guide strand (siRNA **1•15**) did not disrupt RNAi activity, with potency similar to that displayed by the siRNAs containing the G mimic.

Since the siRNA used in this study has only three C residues in the guide strand, with one of them at the 5'-end, we examined the replacement of the internal residues only. Remarkably, the siRNA oligonucleotide (**17**) where C at position 8 within the seed region was substituted by thC, exhibited better gene knockdown than that displayed by the WT. Incorporating thC at position 10 had minimal impact on silencing activity, with potency similar to that of the unmodified siRNA.

In addition to the singly substituted siRNAs discussed above, we also investigated the impact of multiple modifications in the guide strand on the ability of the resulting siRNAs to inhibit protein expression. Two substitutions with each one of the nucleoside analogs thC, thG, thU and thA were explored and one challenging case with five incorporations of thG, was examined. Substitutions at positions 2+6 with thU, as well as at positions 4+5 and 4+7+13+16+19 with thG (oligonucleotides **16** and **10–11**, respectively) were somewhat detrimental to RNAi activity (Figure 4). siRNAs with double incorporation of thC and thA at positions 8+10 and 11+15 (**1•19**, **1•22**, respectively), were nearly as effective as the WT oligonucleotide. Interestingly, the oligonucleotide with thC at positions 8 and 10 (**19**) exhibited slightly better activity than the native siRNA in all concentrations.

In summary, all modified siRNA duplexes containing substitutions of the native nucleosides with thA, thC, thG and thU, synthetic alphabet letters, were found to display potent cellular interference activity. In general, replacing native pyrimidines with their synthetic surrogates, thC and thU, appears to be slightly more disruptive when compared to the purine replacements. This is not entirely unexpected, due to the sterically more demanding fusion of the thiophene at the pyrimidine's 5,6-positions. Multiple incorporations of modified letters, while overall more detrimental, resulted in highly modified siRNA duplexes with respectable interference activity. Even with the poorest performance, seen for duplexes containing two modifications within the seed region, interference activity of above 50% (compared to the wild type activity) was seen at all concentrations. While not without exceptions, the interference activity followed the relative thermal stability of the siRNA duplexes. Although duplex stability alone cannot necessarily serve as a reliable “high resolution” predictor for cellular potency, this suggests that disrupting the conformational

and solvation integrity of the siRNA duplex at certain key domains is likely to negatively impact its interaction with the interference machinery.

We recognize the broad spectrum of RNA interference activities and their dependency on numerous factors, including transfection efficiency, duplex stability, and recognition by the required proteins, etc. Hence, some of the observations made above might be somewhat specific to this particular dGFP-specific siRNA. Nevertheless, the overall excellent performance of highly modified letters, where a thiophene heterocycle replaces the native imidazole, coupled to additional recent observations^{25–27} suggest great utility for such isomorphous RNA building blocks.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the NIH (grant No. GM 069773 to YT) and the W.M. Keck Foundation (to SFD and YT) for support.

Notes and references

1. Hannon GJ. *Nature*. 2002; 418:244. [PubMed: 12110901]
2. Mello CC, Conte D. *Nature*. 2004; 431:338. [PubMed: 15372040]
3. Meister G, Tuschl T. *Nature*. 2004; 431:343. [PubMed: 15372041]
4. Mello CC. *Angew Chem Int Edit*. 2007; 46:6985.
5. Fire AZ. *Angew Chem Int Edit*. 2007; 46:6967.
6. Kurreck J. *Angew Chem Int Edit*. 2009; 48:1378.
7. Carpenter AE, Sabatini DM. *Nat Rev Genet*. 2004; 5:11. [PubMed: 14708012]
8. Moffat J, Sabatini DM. *Nat Rev Mol Cell Bio*. 2006; 7:177. [PubMed: 16496020]
9. Dorsett Y, Tuschl T. *Nat Rev Drug Discov*. 2004; 3:318. [PubMed: 15060527]
10. Echeverri CJ, Perrimon N. *Nat Rev Genet*. 2006; 7:373. [PubMed: 16607398]
11. Johnson, PHE. *RNA Interference, Application to Drug Discovery and Challenges to Pharmaceutical Development*. John Wiley & Sons; NJ: 2011. p. 307
12. Ender C, Meister G. *J Cell Sci*. 2010; 123:1819. [PubMed: 20484662]
13. Behlke MA. *Oligonucleotides*. 2008; 18:305. [PubMed: 19025401]
14. Watts JK, Deleavey GF, Damha MJ. *Drug Discov Today*. 2008; 13:842. [PubMed: 18614389]
15. Terrazas M, Kool ET. *Nucleic Acids Res*. 2009; 37:346. [PubMed: 19042976]
16. Chernolovskaya EL, Zenkova MA. *Curr Opin Mol Ther*. 2010; 12:158. [PubMed: 20373259]
17. Bramsen JB, et al. *Nucleic Acids Res*. 2009; 37:2867. [PubMed: 19282453]
18. Peacock H, Fucini RV, Jayalath P, Ibarra-Soza JM, Haringsma HJ, Flanagan WM, Willingham A, Beal PA. *J Am Chem Soc*. 2011; 133:9200. [PubMed: 21612237]
19. Wahba AS, Azizi F, Deleavey GF, Brown C, Robert F, Carrier M, Kalota A, Gewirtz AM, Pelletier J, Hudson RHE, Damha MJ. *Acs Chem Biol*. 2011; 6:912. [PubMed: 21667942]
20. Peacock H, Kannan A, Beal PA, Burrows CJ. *J Org Chem*. 2011; 76:7295. [PubMed: 21834582]
21. Shin D, Sinkeldam RW, Tor Y. *J Am Chem Soc*. 2011; 133:14912. [PubMed: 21866967]
22. Samanta PK, Manna AK, Pati SK. Theoretical support for their high similarity to the native nucleobases has been reported. *J Phys Chem B*. 2012; 116:7618. [PubMed: 22671305]
23. Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF. *Nat Biotechnol*. 2009; 27:567. [PubMed: 19448630]

24. For the synthesis of ^{13}C , see : Srivatsan SG, Weizman H, Tor Y. *Org Biomol Chem*. 2008; 6:1334. [PubMed: 18385838]
25. Liu W, Shin D, Tor Y, Cooperman BS. *ACS Chemical Biology*. 2013; 8:2017. [PubMed: 23865809]
26. Sinkeldam RW, McCoy LS, Shin D, Tor Y. *Angewandte Chemie International Edition*. 2013; 52:14026.
27. McCoy LS, Shin D, Tor Y. *J Am Chem Soc*. 2014; 136:15176. [PubMed: 25255464]

Fig. 1.
Basic features of siRNA-mediated gene silencing.

Fig. 2.
Isomorphic RNA alphabet.

Fig. 3.

Gene expression of dGFP at 48 hr for all siRNAs; Lipo = lipofectamin only; CTR = buffer; Luc2 = luciferase2; WT = wild type; grey = 1 nM, red = 5 nM, blue = 10 nM, cyan = 50 nM.

Fig. 4.

Gene knockdown and duplex stability compared to WT; black square ■ = 5 nM, red dot • = 10 nM, blue inverted triangle ▼ = T_m .

Scheme 1.

Synthesis of thieno[3,4-*d*]pyrimidine phosphoramidites.^a

^a Reagents and conditions: (a) (i) di-*t*-BuSi(OTf)₂, DMF, 0 °C; (ii) TBDMSCl, Im, 0 °C–RT, 68 % for 2 steps; (iii) *N,N*-diisobutylformamidinium dimethyl acetal, DMF, 87 %; (b) (i) HF-Py, CH₂Cl₂, 0 °C, 86 %; (ii) DMTrCl, Py, 69 %; (iii) 2-cyanoethyl *N,N*-diisopropylchlorophosphoramidite, *i*Pr₂NEt, DCM, 0 °C–RT, 95 %; (c) (i) DMTrCl, Py, 76 %; (ii) TOMCl, di-*tert*-butyltin dichloride, *i*Pr₂NEt, DCE, 80 °C, 19 %; (d) 2-cyanoethyl *N,N*-diisopropylchlorophosphoramidite, *i*Pr₂NEt, DCM, 0 °C–RT, 94 %; (e) (i) DMF-DMA, DMF, 89 %; (ii) di-*t*-BuSi(OTf)₂, DMF, 0 °C–RT; (iii) TBDMSCl, Im, 66 % for 2 steps; (f) (i) HF-Py, CH₂Cl₂, 92 %; (ii) DMTrCl, Py, 0 °C, 95 %; (iii) 2-cyanoethyl *N,N*-diisopropylchlorophosphoramidite, *i*Pr₂NEt, DCM, 0 °C–RT, 57 %; (g) (i) *N,N*-diisobutylformamidinium dimethyl acetal, DMF, 85 %; (ii) DMTrCl, Py, 74 %; (iii) TOMCl, di-*tert*-butyltin dichloride, *i*Pr₂NEt, DCE, 80 °C, 41 %; (h) 2-cyanoethyl *N,N*-diisopropylchlorophosphoramidite, *i*Pr₂NEt, DCM, 0 °C–RT, 81 %;

siRNA Duplexes studied. All siRNA, excluding Luc2 (see below), have a native sugar phosphate backbone.

Table 1

NO.	Duplex	Sequence ^d	T _m (°C) ^b	T _m ^c
1	WT ^d	3'-TUG ACC CAC GAG UCC AUC ACC-5' 5'-C UGG GUG CUC AGG UAG UGG UT-3'	74.8	0.0
3	Luc2 ^e	3'-TUA AAC UUA GAA CAU UAG GAC-5' 5'-U UUG AAU CUU GUA AUC CUG UT-3'	ND ^f	ND
5	G4	5'- C UGG GUG CUC AGG UAG UGG UT-3',	74.3	-0.5
6	G7	5'- C UGG GU ^g CUC AGG UAG UGG UT-3',	75.4	+0.6
7	G13	5'- C UGG GUG CUC AG ^g UAG UGG UT-3',	75.3	+0.5
8	G16	5'- C UGG GUG CUC AGG UA ^g UGG UT-3',	75.3	+0.5
9	G19	5'- C UGG GUG CUC AGG UAG UG ^g UT-3',	75.8	+1.0
10	G4-5	5'- C UG ^g GUG CUC AGG UAG UGG UT-3',	75.8	+1.0
11	5G _s	5'- C UG ^g GU ^g CUC AG ^g UA ^g UG ^g UT-3',	71.8	-3.0
12	U2	5'- C UGG GUG CUC AGG UAG UGG UT-3',	74.4	-0.4
13	U6	5'- C UGG GU ^g CUC AGG UAG UGG UT-3',	73.9	-1.1
14	U9	5'- C UGG GUG CUC AGG UA ^g UGG UT-3',	71.9	-2.9
15	U14	5'- C UGG GUG CUC AGG UAG UGG UT-3',	73.0	-1.8
16	U2-6	5'- C UGG GU ^g CUC AGG UAG UGG UT-3',	71.8	-3.0
17	C8	5'- C UGG GUG CU ^g CUC AGG UAG UGG UT-3',	72.4	-2.4

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

NO.	Duplex	Sequence ^d	T_m (°C) ^b	T_m ^c
18	C10	G 5' - C UGG GUG CUC <u>C</u> AGG UAG UGG UT-3'	73.9	-1.1
19	C8-10	G 5' - C UGG GUG <u>CUC</u> AGG UAG UGG UT-3'	72.9	-1.9
20	A11	G 5' - C UGG GUG CUC <u>AGG</u> UAG UGG UT-3'	75.3	+0.5
21	A15	G 5' - C UGG GUG CUC <u>AGG</u> U <u>AG</u> UGG UT-3'	75.3	+0.5
22	A11-15	G 5' - C UGG GUG CUC <u>AGG</u> U <u>AG</u> UGG UT-3'	77.9	+3.1

^a Passenger strands are on top and guide strands below;

^b T_m values were measured at duplex concentrations of 1 μ M in 20 mM sodium cacodylate, pH 7.0, 20 mM NaCl, and 0.5 mM EDTA. Errors of at least two independent measurements were less than 0.8 °C;

^c Difference in T_m compared to **1•2**;

^d wild type;

^e Luciferase2 siRNA served as a negative control and had a modified backbone (2'-hydroxyl groups were fully modified as OMe for purines and replaced with F for pyrimidines);

^f Not determined.